Published November 15, 2006 | Version v1
Journal article

Hypofractionated versus conventionally fractionated radiation therapy for prostate carcinoma: Updated results of a phase III randomized trial

  • 1. Department of Radiation Oncology, Royal Adelaide Hospital, Adelaide (Australia)
  • 2. Department of Gastroenterology, Royal Adelaide Hospital, Adelaide (Australia)
  • 3. Gastrointestinal Investigation Unit, Repatriation General Hospital, Daw Park (Australia)

Description

Purpose: The aim of this study was to compare the toxicity and efficacy of radiation therapy (RT) for localized carcinoma of the prostate, using a hypofractionated (55 Gy/20 fractions/4 weeks) vs. a conventionally fractionated (64 Gy/32 fractions/6.5 weeks) dose schedule. Methods and Materials: A total of 217 patients were randomized to either the hypofractionated (108 patients) or the conventional (109 patients) dose schedule, with planning with two-dimensional (2D) CT scan planning methodology in the majority of cases. All patients were followed for a median of 48 (6-108) months. Gastrointestinal (GI) and genitourinary (GU) toxicity was evaluated before RT and after its completion using modified late effects of normal tissue-subjective, objective, management, analytic (LENT-SOMA) scales and the European Organization for Research and Treatment of Cancer sexual function questionnaire. Efficacy of RT based on clinical, radiologic, and prostate-specific antigen data were also evaluated at baseline and after RT. Results: Gastrointestinal and GU toxicity persisted 5 years after RT and did not differ between the two dose schedules other than in regard to urgency of defecation. However, 1-month GI toxicity was not only worse in patients with the hypofractionated RT schedule but also adversely affected daily activities. Nadir prostate-specific antigen values occurred at a median of 18.0 (3.0-54.0) months after RT. A total of 76 biochemical relapses, with or without clinical relapses, have occurred since; of these, 37 were in the hypofractionated and 39 in the conventional schedule. The 5-year biochemical ± clinical relapse-free and overall survival was 55.9% and 85.3% respectively for all patients, and did not differ between the two schedules. Conclusions: Radiation therapy for prostate carcinoma causes persistent GI toxicity that is largely independent of the two dose schedules. The hypofractionated schedule is equivalent in efficacy to the conventional schedule

Additional details

Identifiers

DOI
10.1016/j.ijrobp.2006.06.005;
PII
S0360-3016(06)00981-3;

Publishing Information

Journal Title
International Journal of Radiation Oncology, Biology and Physics
Journal Volume
66
Journal Issue
4
Journal Page Range
p. 1072-1083
ISSN
0360-3016
CODEN
IOBPD3

INIS

Country of Publication
United States
Country of Input or Organization
International Atomic Energy Agency (IAEA)
INIS RN
38020685
Subject category
S62: RADIOLOGY AND NUCLEAR MEDICINE;
Descriptors DEI
ANTIGENS; CARCINOMAS; COMPUTERIZED TOMOGRAPHY; PATIENTS; PLANNING; PROSTATE; RADIATION DOSES; RADIOTHERAPY; TOXICITY
Descriptors DEC
BODY; DIAGNOSTIC TECHNIQUES; DISEASES; DOSES; GLANDS; MALE GENITALS; MEDICINE; NEOPLASMS; NUCLEAR MEDICINE; ORGANS; RADIOLOGY; THERAPY; TOMOGRAPHY

Optional Information

Copyright
Copyright (c) 2006 Elsevier Science B.V., Amsterdam, Netherlands, All rights reserved.